secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envista Holdings Corp (NVST)
CIK:        0001757073
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001757073-25-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05
---------------------------------------------------------------------------

- Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.
- Full-year 2024 net loss $1.12B (incl. impairment), adjusted net income $127M vs $269M in 2023.
- Free cash flow $124M in Q4, up 24% YoY; operating cash flow $132M, up 30%.
- Implants improved with growth in Nobel Biocare, Implant Direct, Alpha-Bio; Spark aligners gained share and gross margin.
- FY2025 guidance: core sales growth 1-3%, adjusted EBITDA margin ~14%, adjusted EPS $0.95-$1.05.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757073/000175707325000005/0001757073-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757073/000175707325000005/nvst-20250205.htm
  HTML page:      https://secwatch.observer/filing/0001757073-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer